Aquestive Therapeutics, Inc. financials

AQST CIK 0001398733

Source: EDGAR filings · Built 2026-06-02T02:21:23Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -52.99M -35.92M -7.38M -10.84M -33.89M -45.98M
EBITDA -70.50M -30.05M -13.76M -39.68M -31.71M -39.45M
Working Capital 101.66M 69.36M 22.66M 360.00K 25.30M 23.52M
Net Debt -71.09M -20.92M 27.11M 11.52M -25.18M 23.27M
Gross Margin 58.35% 68.95% 58.82% 59.34% 71.72%
Operating Margin -159.50% -53.46% -29.86% -88.23% -68.22% -93.55%
Net Margin -188.09% -76.68% -15.56% -114.11% -138.77% -121.67%
Return on Equity (ROE) 248.90% 73.37% 7.39% 45.89% 85.88% 115.02%
Return on Assets (ROA) -52.23% -43.52% -13.71% -95.34% -113.79% -88.71%
Current Ratio 3.14× 4.68× 2.24× 1.01× 2.15× 2.11×
Debt-to-Equity -1.49× -0.84× -0.48× -0.33× -0.03× -1.14×
Effective Tax Rate 0.00% 0.03% -3.21% 0.00% 0.00% 0.00%
Cash Conversion Ratio 0.63× 0.81× 0.81× 0.18× 0.47× 0.81×
Accruals Ratio -0.20× -0.08× -0.03× -0.78× -0.61× -0.16×
SBC % of Revenue 17.12% 12.33% 5.32% 9.19% 13.41% 14.35%
CapEx Coverage -93.30× -224.90× -6.41× -9.59× -36.12× -87.93×
Free Cash Flow Per Share $-0.50 $-0.41 $-0.12 $-0.22 $-0.89 $-1.37

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 17.70× 5.65× 2.74× 1.04× 3.16× 4.03×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 44.55M 57.56M 50.58M 47.68M 50.83M 45.85M
Cost of Goods and Services Sold 18.55M 17.87M 20.83M 19.39M 12.96M
Research and Development Expense 17.19M 20.28M 13.10M 17.48M 17.05M 19.89M
Selling, General and Administrative Expense 79.85M 50.18M 31.75M 52.88M 53.48M 55.89M
Operating Expenses 89.75M 85.51M 88.74M
Operating Income (Loss) -71.05M -30.77M -15.10M -42.07M -34.68M -42.89M
Income Tax Expense (Benefit) 0 -14.00K 245.00K 0 0 0
Net Income (Loss) Attributable to Parent -83.78M -44.14M -7.87M -54.41M -70.54M -55.78M
Earnings Per Share, Basic $-0.78 $-0.51 $-0.13 $-1.12 $-1.85 $-1.66
Weighted Average Number of Shares Outstanding, Basic 106.93M 86.73M 61.26M 48.73M 38.08M 33.65M
Earnings Per Share, Diluted $-0.78 $-0.51 $-0.13 $-1.12 $-1.85 $-1.66
Weighted Average Number of Shares Outstanding, Diluted 106.93M 86.73M 61.26M 48.73M 38.08M 33.65M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 121.17M 71.55M 23.87M 27.27M 28.02M 31.81M
Assets, Current 149.27M 88.22M 40.97M 39.89M 47.26M 44.63M
Assets 160.43M 101.42M 57.42M 57.07M 61.99M 62.88M
Long-term Debt 45.00M 45.00M 45.00M 51.50M
Liabilities, Current 47.61M 18.86M 18.31M 39.53M 21.96M 21.10M
Liabilities 194.09M 161.58M 163.91M 175.62M 144.13M 111.38M
Stockholders' Equity Attributable to Parent -33.66M -60.16M -106.49M -118.55M -82.13M -48.50M
Common Stock, Shares, Outstanding 122.04M 91.41M 68.53M 54.83M 41.23M 34.57M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -52.43M -35.76M -6.38M -9.82M -32.98M -45.46M
Payments to Acquire Property, Plant, and Equipment 562.00K 159.00K 995.00K 1.02M 913.00K 517.00K
Net Cash Provided by (Used in) Investing Activities -562.00K -159.00K -995.00K -2.52M -913.00K -517.00K
Net Cash Provided by (Used in) Financing Activities 102.62M 83.59M 3.97M 11.59M 30.11M 28.46M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (AQST CIK 0001398733), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

MBI

MBIA INC.

TOST

Toast, Inc.

CPRT

COPART, INC.